NORMAL SITUATION

APOTEEK KELLES

Export PDF

Financial year 2025 · closed on 31/12/2025

Net result

59,3 k €

-27.2% YoY

Gross margin

486,6 k €

-7.2% YoY

Equity

1,2 M €

+5.1% YoY

Workforce

5,5 ETP

+17.0% YoY

Company — Normal situation.

Strike-off: 05 septembre 2026

What does APOTEEK KELLES do?

APOTEEK KELLES is a Private limited company incorporated in 1979. It employs on average 5,5 ETP workers (FTE).

Legal situation

● Normal situation

BCE/KBO no. / VAT

BE 0419.591.613

Incorporation

02/07/1979

Legal form

Private limited company

Contributed capital

18 600,00 €

Latest accounts

31/12/2025

Average workforce

5,5 ETP

Joint committees (1)

Signals

ProfitableSolid equityGood liquidityPositive cashflowPositive EBITDAHealthy social debts

View the BCE/KBO Public Search record →

Health score

Available with a Rovalta subscriptionTry for 7 days

Recommended credit limit

✦ Verdict · Analyst summary

Financials

Trend over 20 financial years

	2025		2024		2023		2022		2021		2020		2019		2018		2017		2016		2015		2014		2013		2012		2011		2010		2009		2008		2007		2006
Income statement
Gross margin	486,6 k €	-7.2%	524,4 k €	+2.7%	510,4 k €	+2.0%	500,6 k €	+27.5%	392,5 k €	-11.5%	443,4 k €	+6.3%	417 k €	+5.2%	396,5 k €	+37.8%	287,7 k €	-9.7%	318,5 k €	-6.1%	339,3 k €	+20.8%	280,7 k €	+10.7%	253,7 k €	-9.3%	279,6 k €	+15.4%	242,2 k €	+15.1%	210,5 k €	-12.6%	240,9 k €	+50.7%	159,9 k €	+1.2%	158 k €	+34.0%	117,9 k €
EBITDA	166,2 k €	-16.0%	198 k €	-1.2%	200,4 k €	+6.6%	187,9 k €	+27.2%	147,7 k €	-31.3%	215 k €	+15.2%	186,7 k €	+33.6%	139,8 k €	+35.1%	103,4 k €	-34.5%	157,8 k €	-20.7%	198,9 k €	+32.5%	150,1 k €	+21.6%	123,5 k €	-17.0%	148,7 k €	+26.5%	117,6 k €	+19.6%	98,3 k €	-31.6%	143,6 k €	+82.2%	78,8 k €	-22.1%	101,2 k €	-23.3%	131,9 k €
Operating result	86,7 k €	-25.3%	116 k €	+1.4%	114,4 k €	+5.2%	108,8 k €	+38.4%	78,6 k €	-46.5%	147,1 k €	+163%	55,9 k €	+118%	25,7 k €	+157%	10 k €	-90.6%	106 k €	-25.5%	142,4 k €	+64.3%	86,7 k €	+122%	39,1 k €	-38.6%	63,6 k €	+43.0%	44,5 k €	+62.9%	27,3 k €	-64.0%	75,9 k €	+437%	14,1 k €	-41.0%	24 k €	-53.6%	51,7 k €
Net result	59,3 k €	-27.2%	81,5 k €	+2.6%	79,4 k €	-4.6%	83,3 k €	+32.0%	63,1 k €	-46.0%	116,8 k €	+125%	51,8 k €	+156%	20,2 k €	+411%	4 k €	-94.4%	70,3 k €	-27.3%	96,6 k €	+73.0%	55,9 k €	+169%	20,8 k €	-9.0%	22,8 k €	-19.0%	28,2 k €	+158%	10,9 k €	-79.0%	52,2 k €	+2646%	1,9 k €	+20.0%	1,6 k €	-96.3%	42,5 k €
Balance sheet
Equity	1,2 M €	+5.1%	1,2 M €	+7.6%	1,1 M €	+8.0%	993,3 k €	+9.1%	910 k €	+7.4%	847 k €	+16.0%	730,2 k €	+7.6%	678,4 k €	+3.1%	658,2 k €	+0.6%	654,2 k €	+12.0%	584 k €	+19.8%	487,4 k €	+12.9%	431,5 k €	+5.1%	410,7 k €	+5.9%	387,9 k €	+7.8%	359,7 k €	+3.1%	348,8 k €	+17.6%	296,6 k €	+0.6%	294,7 k €	+0.5%	293,1 k €
Total assets	1,7 M €	+22.7%	1,4 M €	+1.9%	1,4 M €	-0.6%	1,4 M €	+6.2%	1,3 M €	+4.2%	1,3 M €	+6.9%	1,2 M €	+5.4%	1,1 M €	-2.4%	1,1 M €	+28.3%	887,3 k €	+0.3%	884,5 k €	+12.1%	789,3 k €	-2.2%	807,1 k €	-31.0%	1,2 M €	+31.4%	890 k €	+24.2%	716,5 k €	-8.9%	786,4 k €	+9.7%	717 k €	-4.4%	750,3 k €	-6.5%	802 k €
Cash	335,5 k €	+52.0%	220,8 k €	-3.2%	228,1 k €	-15.8%	270,9 k €	+71.2%	158,2 k €	+13.0%	140 k €	-10.2%	155,9 k €	-45.9%	288,4 k €	+25.7%	229,5 k €	+43.1%	160,4 k €	+6.5%	150,6 k €	+59.8%	94,2 k €	-8.7%	103,1 k €	-7.1%	111,1 k €	-3.3%	114,9 k €	+24.8%	92 k €	+65.9%	55,5 k €	-17.7%	67,5 k €	-44.8%	122,2 k €	+53.0%	79,9 k €
Debts	507,1 k €	+105%	247,9 k €	-18.3%	303,3 k €	-22.4%	390,6 k €	-0.7%	393,3 k €	-2.6%	403,8 k €	-8.3%	440,4 k €	+1.8%	432,5 k €	-9.9%	479,9 k €	+106%	233,1 k €	-22.4%	300,5 k €	+12.4%	267,4 k €	-22.0%	342,8 k €	-53.2%	732,3 k €	+46.0%	501,5 k €	+40.6%	356,8 k €	-18.5%	437,6 k €	+5.1%	416,2 k €	-7.6%	450,6 k €	-11.2%	507,7 k €
Other
Workforce	5,5 ETP	+17.0%	4,7 ETP	+2.2%	4,6 ETP	-4.2%	4,8 ETP	+9.1%	4,4 ETP	+7.3%	4,1 ETP	0.0%	4,1 ETP	-12.8%	4,7 ETP	+42.4%	3,3 ETP	+22.2%	2,7 ETP	+8.0%	2,5 ETP	0.0%	2,5 ETP	0.0%	2,5 ETP	0.0%	2,5 ETP	-3.8%	2,6 ETP	0.0%	2,6 ETP	+8.3%	2,4 ETP	+41.2%	1,7 ETP	+54.5%	1,1 ETP	+10.0%	1,0 ETP

Governance

Board of directors

Seen on filing of 31/12/2025 · 2 active · 2 ended

Active mandates

AN MARIN

Director

Active

ARNAUD BERKEN

Director

Active

Ended mandates

PHARM@21

Manager · 0876.529.018

Represented by Joris Van Brempt

Ended

PHARM@21

Director · 0876.529.018

Represented by Joris Van Brempt

Ended

Annual accounts

Full financial information

	2025	2024	2023	2022	2021	2020
Type of account	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	26/08/2026	28/08/2025	30/08/2024	26/08/2023	30/08/2022	30/08/2021
General meeting	30/05/2026	31/05/2025	25/05/2024	27/05/2023	28/05/2022	29/05/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days

Filings

Annual accounts filings

21 filings with the NBB

Model	Closing	General meeting	Filed	Language	Document
Abridged model	31/12/2025	30/05/2026	26/08/2026	Dutch	PDF
Abridged model	31/12/2024	31/05/2025	28/08/2025	Dutch	PDF
Abridged model	31/12/2023	25/05/2024	30/08/2024	Dutch	PDF
Abridged model	31/12/2022	27/05/2023	26/08/2023	Dutch	PDF
Abridged model	31/12/2021	28/05/2022	30/08/2022	Dutch	PDF
Abridged model	31/12/2020	29/05/2021	30/08/2021	Dutch	PDF
Abridged model	31/12/2019	30/05/2020	31/08/2020	Dutch	PDF
Abridged model	31/12/2018	25/05/2019	30/08/2019	Dutch	PDF
Abridged model	31/12/2017	26/05/2018	24/08/2018	Dutch	PDF
Abridged model	31/12/2016	27/05/2017	31/08/2017	Dutch	PDF
Abridged model	31/12/2015	28/05/2016	30/08/2016	Dutch	PDF
Abridged model	31/12/2014	30/05/2015	31/08/2015	Dutch	PDF
Abridged model	31/12/2013	31/05/2014	29/08/2014	Dutch	PDF
Abridged model	31/12/2012	25/05/2013	29/08/2013	Dutch	PDF
Abridged model	31/12/2011	26/05/2012	30/08/2012	Dutch	PDF
Abridged model	31/12/2010	27/05/2011	30/08/2011	Dutch	PDF
Abridged model	31/12/2009	29/05/2010	27/08/2010	Dutch	PDF
Abridged model	31/12/2008	30/05/2009	28/08/2009	Dutch	PDF
Abridged modelCorrection	31/12/2007	31/05/2008	17/09/2008	Dutch	PDF
Abridged model	31/12/2007	31/05/2008	29/08/2008	Dutch	PDF
Abridged model	31/12/2006	26/05/2007	29/08/2007	Dutch	PDF

Estimate

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2025 · 2 active · 2 ended

Active mandates

AN MARIN

Director

Active

ARNAUD BERKEN

Director

Active

Ended mandates

PHARM@21

Manager · 0876.529.018

Represented by Joris Van Brempt

Ended

PHARM@21

Director · 0876.529.018

Represented by Joris Van Brempt

Ended

Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette

Belgian Official Gazette publications

Restructuring14/09/2026
VERRICHTING GELIJKGESTELD MET FUSIE DOOR OVERNEMING DOOR
PDF
Other05/05/2026
DIVERSEN
PDF
Mandates12/02/2026
ONTSLAGEN - BENOEMINGEN
PDF
Other30/11/2022
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - WIJZIGING RECHTSVORM
PDF
Mandates13/11/2020
ONTSLAGEN - BENOEMINGEN - WIJZIGING RECHTSVORM
PDF
Mandates08/11/2005
ONTSLAGEN - BENOEMINGEN - ALGEMENE VERGADERING - KAPITAAL - AANDELEN - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, )
PDF
Mandates19/10/2005
ONTSLAGEN - BENOEMINGEN
PDF
Capital / shares07/01/2005
KAPITAAL - AANDELEN - ALGEMENE VERGADERING - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, )
PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

2025
Annual accounts 202559,3 k €↓
2024
Annual accounts 202481,5 k €↑
2024
Name changeAPOTEEK KELLES
2023
Annual accounts 202379,4 k €↓
2022
Annual accounts 202283,3 k €↑
2021
Annual accounts 202163,1 k €↓
2021
Name changeAPOTHEEK KELLES
2020
Annual accounts 2020116,8 k €↑
2019
Annual accounts 201951,8 k €↑
2018
Annual accounts 201820,2 k €↑
2017
Annual accounts 20174 k €↓
2016
Annual accounts 201670,3 k €↓
2015
Annual accounts 201596,6 k €↑
2014
Annual accounts 201455,9 k €↑
2013
Annual accounts 201320,8 k €↓
2012
Annual accounts 201222,8 k €↓
2011
Annual accounts 201128,2 k €↑
2010
Annual accounts 201010,9 k €↓
2009
Annual accounts 200952,2 k €↑
2008
Annual accounts 20081,9 k €↑
2007
Annual accounts 20071,6 k €↓
2006
Annual accounts 200642,5 k €
02/07/1979
IncorporationPrivate limited company

10/15	1 240 000	1 180 000	1 050 000
70	8 630 000	8 120 000	7 940 000
9904	412 000	388 000	301 000
17/49	2 970 000	3 140 000	3 380 000
9087	24,3	23,1	21,8

APOTEEK KELLES

Overview

What does APOTEEK KELLES do?

Trend over 20 financial years

Board of directors

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline